title: [Estrogen use in systemic lupus erythematosus].
abstract: The role of exogenous estrogen in the initiation and maintenance of human systemic lupus erythematosus (SLE) remains very controversial. To review the current literature of the safety of using exogenous estrogens in patients with SLE, a Medline search for articles published between 1970 et 2004 regarding this relationship was performed. Although cohort studies suggest an increase in the incidence of SLE with both oral contraceptives and hormone replacement therapy, recent retrospective studies suggest that the risk of flares is not increased with hormone replacement therapy. Large prospective double blind placebo controlled studies inclusive of all ethnic groups such as the Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA) trial had to provide the basis for definitive recommendations but it had been interrupted after WHI study results.
authors.affiliation: Service de médecine interne, hôpital-Habib-Thameur, 8, rue Ali-Ben-Ayed, 1008 Montfleury, Tunisie. s.ktari@lycos.com
authors.forename: S
authors.initials: S
authors.lastname: Ketari
authors.forename: O
authors.initials: O
authors.lastname: Cherif
authors.forename: F
authors.initials: F
authors.lastname: Boussema
authors.forename: S
authors.initials: S
authors.lastname: Kochbati
authors.forename: B
authors.initials: B
authors.lastname: Ben Dhaou
authors.forename: L
authors.initials: L
authors.lastname: Rokbani
mesh_terms: D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000188:drug therapy*; D012449:Safety
chemical_list: D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens